Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANDEM: tropifexor + cenicriviroc in adults with NASH and liver fibrosis
2017-004208-24Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tropifexor and cenicriviroc in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability over 48 weeks and Histologic improvement after 48 weeks. Started Jun 2018; status: completed.
02
Drugs
tropifexorcenicriviroc
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2017-004208-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004208-24.